Mark Gergen

Mark Gergen

Plus aucun poste en cours
63 ans
Health Technology
Commercial Services
Consumer Services

Profil

Mark J.
Gergen
is an Independent Director at Aristea Therapeutics, Inc. He previously served as the Executive Chairman at Poseida Therapeutics, Inc. from 2024 to 2025.
Mark also held positions as a Director at Aperio Technologies, Inc., Chief Financial & Development Officer at Advanced Tissue Sciences, Inc. from 1999 to 2003, and Senior Vice President-Corporate Development at Amylin Pharmaceuticals, Inc. from 2005 to 2012.
He was also a Principal at Jostens, Inc. and Medtronic, Inc. Mark served as the Chief Operating Officer & Senior Vice President at Halozyme Therapeutics, Inc. from 2016 to 2017, and as the Executive Vice President at CardioNet LLC from 2003 to 2005.
He was also a Principal at Premier Healthcare Solutions, Inc. and served as the Chief Operating Officer, Secretary & Executive VP at Mirati Therapeutics, Inc. in 2016.
Mr. Gergen obtained his undergraduate degree from Minot State University and his graduate degree from The University of Minnesota Law School.

Anciens postes connus de Mark Gergen

SociétésPosteFin
POSEIDA THERAPEUTICS, INC. Directeur Général 01/01/2024
HALOZYME THERAPEUTICS, INC. Directeur des opérations 29/09/2017
MIRATI THERAPEUTICS Directeur des opérations 16/09/2016
Corporate Officer/Principal 01/11/2012
Corporate Officer/Principal 01/03/2005
Voir l'expérience en détail de Mark Gergen

Formation de Mark Gergen

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

61

Relations au 1er degré

13

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées13

Commercial Services

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

  1. Bourse
  2. Insiders
  3. Mark Gergen